topic

258 Scientific correlatives from LCCC 1525: a phase II study of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer
Mark Woodcock, Carey Anders, Amanda Van Swearingen, Dominic Moore, Maria Sambade, Luz Cuaboy, Amy Garrett, Karen McKinnon, Kristen Cowens, Dante Bortone, Benjamin Calhoun, Lisa Carey, Claire Dees, Trevor Jolly, Hyman Muss, Katherine Reeder-Hayes, Rebecca Kaltman, Rachel Jankowitz, Vinay Gudena, Oludamilola Olajide, Charles Perou, Benjamin Vincent, Jonathan Serody

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A156-A157; DOI: 10.1136/jitc-2020-SITC2020.0258
282 Pan-tumor analysis of the association between PD-L1 combined positive score and response to pembrolizumab monotherapy
Lingkang Huang, Jared Lunceford, Junshui Ma, Kenneth Emancipator

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A172-A173; DOI: 10.1136/jitc-2020-SITC2020.0282
284 Real World Data of Sequencing Immune Checkpoint Inhibitors (ICI) after Initial ICI
Krishna Gunturu, Muhammad Awidi, Rojer Ranjit, Brendan Connell, Rachel Carrasquillo, Brigitte Gil, Natalie Dalbo, Lewena Maher, Seanna Reilly, Stephanie McDonald, Philip Tsoukas, Linda Voner

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A174; DOI: 10.1136/jitc-2020-SITC2020.0284
285 Phase I clinical trial evaluating the safety of ADP-A2M10 in patients with MAGE-A10⁺ head and neck, melanoma, or urothelial tumors
David Hong, Marcus Butler, Russell Pachynski, Ryan Sullivan, Partow Kebriaei, Sarah Boross-Harmer, Matthew Frigault, Ecaterina Dumbrava, Amy Sauer, Francine Brophy, Jean-Marc Navenot, Svetlana Fayngerts, Jane Bai, Elliot Norry, Paula Fracasso

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A174; DOI: 10.1136/jitc-2020-SITC2020.0285
287 Safety and antitumor activity of indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor KHK2455 in combination with anti-CCR4 monoclonal antibody mogamulizumab in patients with advanced solid tumors
Solmaz Sahebjam, Jameel Muzaffar, Timothy Yap, David Hong, Olivier Rixe, Ursa Brown-Glaberman, Andreea Varga, Christophe Massard, Capucine Baldini, Sergey Efuni, Barbara Kapelan, Yi Liu, Eniola Ogunmefun, Tomonori Tayama, Henry Zhao, Denis Healy, Robert Latek, Daisuke Nakashima, Emrullah Yilmaz

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A175-A176; DOI: 10.1136/jitc-2020-SITC2020.0287
286 Tumor targeting and tissue biodistribution of RO7122290, a novel FAP-targeted 4–1BB (CD137) agonist, in patients with advanced solid tumors, using [89Zr]-RO7122290 as a PET tracer
Maria Jose Garcia Velloso, Ivan Penuelas, Mariano Ponz-Sarvise, Miguel Sanmamed, Maria Rodriguez-Ruiz, Ignacio Melero, Danielle Vugts, Ronald Boellaard, Marc Huisman, Guus van Dongen, Ernesto Guarin, Florian Heil, Maurizio Ceppi, Marta Canamero, Camilla Matheisen, Francois Iglesias, Radoiane Helbaj, Oliver Krieter, Michael Hettich

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A175; DOI: 10.1136/jitc-2020-SITC2020.0286
289 PGV-001: a phase 1 trial of a personalized neoantigen peptide vaccine for the treatment of malignancies in the adjuvant setting
Thomas Marron, Julia Kodysh, Alex Rubinsteyn, John Finnigan, Ana Blazquez, Mansi Saxena, Marcia Meseck, Timothy O’Donnell, Daniela Delbeau, Matthew Galsky, Deborah Doroshow, Brett Miles, Krysztof Misiukiewicz, Hanna Irie, Amy Tiersten, Samir Parekh, Marshall Posner, Andrea Wolf, John Mandeli, Jeffrey Hammerbacher, Michael Donovan, Rachel Brody, Sacha Gnjatic, Eric Schadt, Philip Friedlander, Nina Bhardwaj

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A177; DOI: 10.1136/jitc-2020-SITC2020.0289
293 Resultsof the first-in-human clinical trial with personalized multi-target adoptive cell therapy (ACTolog IMA101)
Apostolia Tsimberidou, Kerstin Guenther, Amir Alpert, Borje Andersson, Zoe Coughlin, Jens Fritsche, Norbert Hilf, Patrick Hwu, Mamta Kalra, Sabrina Kuttruff-Coqui, Dominik Maurer, Regina Mendrzyk, Ali Mohamed, Becky Norris, Anna Nowak, Rita Ort, Carsten Reinhardt, Fabian Richter, Arun Satelli, Oliver Schoor, Kerry Sieger, Harpreet Singh, David Vining, Claudia Wagner, Toni Weinschenk, Cassian Yee, Steffen Walter

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A179; DOI: 10.1136/jitc-2020-SITC2020.0293
295 First-in-human Phase I trial of IBI188, an anti-CD47 targeting monoclonal antibody, in patients with advanced solid tumors and lymphomas
Nehal Lakhani, Marlana Orloff, Siqing Fu, Ying Liu, Yan Wang, Hui Zhou, Kedan Lin, Fang Liu, Shuling Yan, Amita Patnaik

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A180; DOI: 10.1136/jitc-2020-SITC2020.0295
296 Immune correlates of clinical response to Avelumab in patients with advanced thymic epithelial tumors
Yo-Ting Tsai, Arun Rajan, James Gulley, Jeffrey Schlom, Renee Donahue

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A181; DOI: 10.1136/jitc-2020-SITC2020.0296

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages